Clinical experience and management considerations with long-acting risperidone

References

• Buchanan RW, Carpenter WT. Schizophrenia: introduction and overview. In: Sadock VA, editor. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, 7th edn. Philadelphia, Pa: Lippincott Williams & Wilkins 2000. pp. 1096–110
   Google Scholar
• Carpenter Jr WT, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138–48
   PubMed Web of Science ®Google Scholar
• Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 1991;48:333–9
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psych 2002;159:1–50
   Web of Science ®Google Scholar
• Lambert TJ, Castle DJ. Pharmacological approaches to the management of schizophrenia. Med J Aust 2003;178(Suppl): S57–61
   Google Scholar
• Gerlach J. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 1999;60(Suppl 23):20–4
   PubMedGoogle Scholar
• Bouchard RH, Merette C, Pourcher E, et al. Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. J Clin Psychopharmacol 2000;20:295–304
   PubMed Web of Science ®Google Scholar
• Martyns-Yellowe IS. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment. West Afr J Med 1994;13:200–3
   PubMedGoogle Scholar
• Kennedy E, Song F, Hunter R, et al. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst Rev 2000:CD000440
   Google Scholar
• Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16:473–84
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553–64
   PubMed Web of Science ®Google Scholar
• Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209–22
   PubMed Web of Science ®Google Scholar
• Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003;7:1–193
   PubMedGoogle Scholar
• Moller HJ. Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 1993;3:1–11
   PubMed Web of Science ®Google Scholar
• Gharabawi GM, Bossie CA, Zhu Y, et al. An assessment of emergent tardive dyskinesia and existing dyskinesias in patients receiving long-acting injectable risperidone: Results from a long- term study. Schizophr Res 2005;77:129–39
   PubMed Web of Science ®Google Scholar
• Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004;65(Suppl 9):16–20
   PubMed Web of Science ®Google Scholar
• Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004;65 (Suppl 9):21–4
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19:1–93
   PubMed Web of Science ®Google Scholar
• Miller del D. Atypical antipsychotics: sleep, sedation and efficacy. Prim Care Companion J Clin Psychiatry 2004;6:3–7
   PubMedGoogle Scholar
• Citrome LL. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today (Barc) 2004;40:445–64
   PubMed Web of Science ®Google Scholar
• Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561–6
   PubMed Web of Science ®Google Scholar
• Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596–601
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16–22
   Google Scholar
• Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103–8
   PubMed Web of Science ®Google Scholar
• Weiden P, Zygmunt A. Medication noncompliance in schizo- phrenia. Part I. Assessment. J Pract Psychiatry Behav Health 1997;3:106–10
   Google Scholar
• Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European neuropsychopharmacology consensus conference in Siena, Italy. Eur Neuropsychopharmacol 1998;8:55–66
   PubMed Web of Science ®Google Scholar
• Valenstein M, Copeland LA, Owen R, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001;62:545–51
   PubMed Web of Science ®Google Scholar
• Velligan DI, Miller AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry 1999;60(Suppl 23):25–8
   PubMedGoogle Scholar
• American Psychiatric Association: Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997;154(Suppl 4):1–63
   Web of Science ®Google Scholar
• Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmaco- kinetics and pharmacodynamics. J Clin Psychiatry 2003;64(Suppl 16):18–23
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984;45:50–9
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12 month evaluation of the first long-acting 2nd generation antipsychotic. J Clin Psychiatry 2003;64:1250–7
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084–9
   PubMed Web of Science ®Google Scholar
• Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004;19:241–9
   PubMed Web of Science ®Google Scholar
• Lasser R, Bossie C, Gharabawi G, et al. Patients with schizo- phrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19:219–25
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125–32
   PubMed Web of Science ®Google Scholar
• Van Os J, Bossie C, Lasser R. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004;19:229–32
   Google Scholar
• Risperdal® Consta™ (Risperidone) Long-acting Injection. Johnson & Johnson prescribing information, April, 2005. Available from: http://www.risperdalconsta.com/active/janus/en_US/assets/common/company/pi/risperdalconsta.pdf [Accessed 01 December 2005]
   Google Scholar
• Eerdekens M, Karcher K, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting injectable risperidone in schizophrenia. Schizophrenia Res 2004;70:91–100
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Euro Neuropsychopharmacol 2005:15:111–17
   PubMed Web of Science ®Google Scholar
• Gilbody S, Wahlbeck K, Adams C. Randomised controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatr Scand 2002;105:243–51
   Google Scholar
• Moller H, Llorca PM, Sachetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20:121–30
   PubMed Web of Science ®Google Scholar
• Vauth R, Braendle D, Latif MA. Direct switch from atypical antipsychotics to long-acting injectable risperidone in patients with schizophrenia (StoRMI trial). Schizo Res 2004;67 (Suppl 1):1–320: Abstracts of the Winter Workshop, 7–13 February, Davos, Switzerland
   Google Scholar
• Chue P, Devos E, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. Value Health 2002;5:229
   Google Scholar
• Eriksson L, Almqvist A, Mehnert A, et al. Long-acting risperidone significantly reduces the need for institutional psychiatric care. American College of Neuropsychopharmacologists 42nd Annual Meeting, 7–11 December, 2003. San Juan, Puerto Rico: Abstract 169
   Google Scholar
• Turner M, Eerdekens M, Jacko M. Long-acting injectable risperidone: safety and efficacy in patients switched from conventional depot antipsychotics. Presented at the American Psychiatric Association Meeting, 17–22 May 2003, San Francisco, CA 2003: poster No. NR198
   Google Scholar
• Lasser RA, Bossie CA, Zhu Y, et al. Efficacy and safety of long- acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry 2004;19:898–905
   PubMed Web of Science ®Google Scholar
• Gharabawi G, Lasser R, Bossie C, et al. Enhanced one-year outcomes with three doses of long-acting injectable risperidone in 336 chronically psychotic, stable patients switched from oral risperidone. Presented at the American College of Neuropsychopharmacology 41st Annual Meeting, San Juan, Peurto Rico: abstract 175 2002:175
   Google Scholar
• Bouhours P, Rendall M, Pajonk G. Efficacy and safety of long- acting injectable risperidone in patients with schizophrenia (StoRMi trial). Schizo Res 2004;67\(Suppl 1):1–320: Abstracts of the Winter Workshop, 7–13 February, Davos, Switzerland
   Google Scholar
• Lasser R, Bossie C, Zhu Y, et al. Long-acting risperidone in young adults with schizophrenia or schizoaffective disorder. Poster presented at American Psychiatric Association 1–6 May 2004, New York. Poster No. NR641
   Google Scholar
• Saleem P, Firmino H, Parellada E, et al. Young patients (18–30 years) with schizophrenia and schizoaffective disorder: results of direct switching to long-acting injectable risperidone (StoRMi trial). Schizo Res 2004;67\(Suppl 1):1–320: Abstracts of the Winter Workshop, 7–13 February, Davos, Switzerland
   Google Scholar
• Lasser R, Bossie C, Gharabawi G, et al. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: A 12-month open trial. Int J Neuropsychopharmacol 2004;8:1–12
   Google Scholar
• Lasser R, Rodriguez S, Turkoz I, et al. Optimization of long- acting risperidone for maintenance therapy in schizophrenia. Presented at the International Congress on Schizophrenia Research, 2–6 April 2005, Savannah
   Google Scholar
• Lasser R, Bossie CA, Gharabawi G, et al. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 2004;83:263–75
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005; 20:213–21
   PubMed Web of Science ®Google Scholar
• Nasrallah H, Duchesne I, Mehnert A, et al. Health-related quality of life with schizophrenia during treatment with long- acting risperidone injection. J Clin Psychiatry 2004;65:531–6
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Rabinowitz J, Kemmler G, et al. Perceived functioning, well-being and association with psychiatric symptomatology in clinically stable schizophrenia patients treated with long-acting risperidone for 1 year. Br J Psychiatry 2005;187:131–6
   PubMed Web of Science ®Google Scholar
• Rodriguez S, Locklear J, Turkoz I, et al. Maintenance therapy with long-acting risperidone: functioning and quality of life in patients with schizophrenia and schizoaffective disorder. Presented as a poster at American Psychiatric Association 22–26 May 2005, Atlanta
   Google Scholar
• Andreasen N, Carpenter W, Kane J, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441–9
   PubMed Web of Science ®Google Scholar
• Lasser R, Bossie CA, Gharabawi GM, et al. Symptom remission in schizophrenia: results from an open-label 50-week study of long-acting risperidone. Schizo Res 2005;77:215–27
   PubMed Web of Science ®Google Scholar
• Pandarakalam JP. Atypical and conventional depot medications. Hosp Med 2003;64:658–63
   PubMed Web of Science ®Google Scholar
• Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001;62:855–9
   PubMed Web of Science ®Google Scholar
• Keith SJ, Kane JM, Turner M, et al. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 2004;65:120–31
   PubMed Web of Science ®Google Scholar
• Keith S, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatric Serv 2004;55:997–1005
   PubMed Web of Science ®Google Scholar
• Gharabawi G, Bossie CA, Zhu Y, et al. Insight in stable patients with schizophrenia receiving long-acting risperidone. Int Journal of Neuropsychopharmacol 2004;7:S1–503
   PubMedGoogle Scholar
• Gaebel W, Janner M, Frommann N, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002;53:145–59
   PubMed Web of Science ®Google Scholar
• Pietzcker A, Gaebel W, Kopcke W, et al. Intermittent vs maintenance neuroleptic long-term treatment in schizophrenia – two-year results of a German multicenter study. J Psychiatric Res 1993;27:321–39
   Web of Science ®Google Scholar
• McGlashan T. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 1988;14:515–42
   PubMed Web of Science ®Google Scholar
• Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999;60(Suppl 23):5–9
   PubMed Web of Science ®Google Scholar
• Fowler IL, Carr VJ, Carter NT, et al. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 1998;24:443–55
   PubMed Web of Science ®Google Scholar
• Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216–22
   PubMed Web of Science ®Google Scholar
• Bergen J, Hunt G, Armitage P, et al. Six-month outcome following a relapse of schizophrenia. Aust N Z J Psychiatry 1998;32:815–22
   PubMed Web of Science ®Google Scholar
• Caldwell CB, Gottesman I. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 1990;16:571–89
   PubMed Web of Science ®Google Scholar
• Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003;12:423–4
   PubMed Web of Science ®Google Scholar
• Buckley PF, Hasan S, Friedman L, et al. Insight and schizophrenia. Compr Psychiatry 2001;42:39–41
   PubMed Web of Science ®Google Scholar
• Aguglia E, De Vanna M, Onor Ml et al. Insight in person with schizophrenia. Effects of switching from conventional neuro-leptics to atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:1299–33
   Google Scholar
• Urioste R, Lasser R, Gharabawi G, et al. Patient acceptance and long-acting risperidone: START program, GAIN approach. Presented as a poster at American Psychiatric Association 22–26 May 2005, Atlanta
   Google Scholar
• Keith S. Use of long-acting risperidone. Psychiatr Serv 2005;56:106–7 [letter]
   Google Scholar
• Marder S, Conley R, Ereshefsky L, et al. Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003; 64(Suppl 16):41–6
   PubMedGoogle Scholar